X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare J.B.Chemicals with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

J.B.CHEMICALS vs VENUS REMEDIES - Comparison Results

J.B.CHEMICALS    Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    J.B.CHEMICALS VENUS REMEDIES J.B.CHEMICALS/
VENUS REMEDIES
 
P/E (TTM) x 17.4 -4.1 - View Chart
P/BV x 2.4 0.2 1,546.4% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 J.B.CHEMICALS   VENUS REMEDIES
EQUITY SHARE DATA
    J.B.CHEMICALS
Mar-16
VENUS REMEDIES
Mar-18
J.B.CHEMICALS/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs318126 252.7%   
Low Rs20061 326.5%   
Sales per share (Unadj.) Rs148.0301.8 49.0%  
Earnings per share (Unadj.) Rs19.1-24.9 -76.7%  
Cash flow per share (Unadj.) Rs23.92.5 941.1%  
Dividends per share (Unadj.) Rs0.500-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs128.9293.3 44.0%  
Shares outstanding (eoy) m84.8212.34 687.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.70.3 564.5%   
Avg P/E ratio x13.6-3.8 -360.7%  
P/CF ratio (eoy) x10.836.7 29.4%  
Price / Book Value ratio x2.00.3 629.5%  
Dividend payout %2.60-   
Avg Mkt Cap Rs m21,9511,154 1,902.5%   
No. of employees `0002.70.9 295.6%   
Total wages/salary Rs m1,841393 468.4%   
Avg. sales/employee Rs Th4,590.94,026.1 114.0%   
Avg. wages/employee Rs Th673.4425.0 158.5%   
Avg. net profit/employee Rs Th592.1-331.8 -178.4%   
INCOME DATA
Net Sales Rs m12,5513,724 337.0%  
Other income Rs m54223 2,407.1%   
Total revenues Rs m13,0933,747 349.5%   
Gross profit Rs m2,055395 520.4%  
Depreciation Rs m412338 121.9%   
Interest Rs m96354 27.0%   
Profit before tax Rs m2,088-275 -758.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m46932 1,484.5%   
Profit after tax Rs m1,619-307 -527.4%  
Gross profit margin %16.410.6 154.4%  
Effective tax rate %22.5-11.5 -195.7%   
Net profit margin %12.9-8.2 -156.5%  
BALANCE SHEET DATA
Current assets Rs m7,7782,638 294.9%   
Current liabilities Rs m4,3582,305 189.1%   
Net working cap to sales %27.28.9 304.7%  
Current ratio x1.81.1 155.9%  
Inventory Days Days55135 40.4%  
Debtors Days Days8046 172.7%  
Net fixed assets Rs m5,7134,871 117.3%   
Share capital Rs m170123 137.4%   
"Free" reserves Rs m10,5473,496 301.7%   
Net worth Rs m10,9373,619 302.2%   
Long term debt Rs m01,374 0.0%   
Total assets Rs m15,5747,509 207.4%  
Interest coverage x22.80.2 10,234.5%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.80.5 162.5%   
Return on assets %11.00.6 1,743.8%  
Return on equity %14.8-8.5 -174.5%  
Return on capital %20.01.6 1,261.9%  
Exports to sales %48.70-   
Imports to sales %7.113.9 51.0%   
Exports (fob) Rs m6,115NA-   
Imports (cif) Rs m889517 172.0%   
Fx inflow Rs m6,1690-   
Fx outflow Rs m1,285517 248.8%   
Net fx Rs m4,884-517 -945.6%   
CASH FLOW
From Operations Rs m1,397514 271.5%  
From Investments Rs m-320-123 260.2%  
From Financial Activity Rs m-1,196-387 308.9%  
Net Cashflow Rs m-1024 -2,435.7%  

Share Holding

Indian Promoters % 55.4 32.9 168.6%  
Foreign collaborators % 0.3 0.0 -  
Indian inst/Mut Fund % 3.4 0.2 1,883.3%  
FIIs % 3.9 0.6 672.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 37.0 66.4 55.7%  
Shareholders   30,437 20,121 151.3%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare J.B.CHEMICALS With:   GSK PHARMA  ASTRAZENECA PHARMA  DISHMAN PHARMA  IPCA LABS  JUBILANT LIFE SCIENCES  

Compare J.B.CHEMICALS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Sell-Off; Sensex Slumps Over 530 Points(Closing)

Share markets in India continued their sell-off seen during the last week and ended the day deep in the red. All sectoral indices traded on a negative note.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2% (Quarterly Result Update)

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

J.B.CHEMICALS SHARE PRICE


Sep 24, 2018 (Close)

TRACK J.B.CHEMICALS

  • Track your investment in J.B.CHEMICALS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

J.B.CHEMICALS 5-YR ANALYSIS

COMPARE J.B.CHEMICALS WITH

MARKET STATS